Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EBIT (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EBIT for 14 consecutive years, with -$19.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 29.27% to -$19.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$69.9 million through Dec 2025, down 32.29% year-over-year, with the annual reading at -$56.0 million for FY2025, 69.51% down from the prior year.
  • EBIT hit -$19.5 million in Q4 2025 for Vistagen Therapeutics, up from -$20.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$6.2 million in Q1 2021 to a low of -$20.1 million in Q3 2025.
  • Historically, EBIT has averaged -$12.9 million across 5 years, with a median of -$12.5 million in 2021.
  • Biggest five-year swings in EBIT: crashed 288.62% in 2021 and later soared 64.61% in 2023.
  • Year by year, EBIT stood at -$10.5 million in 2021, then increased by 7.33% to -$9.8 million in 2022, then rose by 19.28% to -$7.9 million in 2023, then tumbled by 91.78% to -$15.1 million in 2024, then fell by 29.27% to -$19.5 million in 2025.
  • Business Quant data shows EBIT for VTGN at -$19.5 million in Q4 2025, -$20.1 million in Q3 2025, and -$15.8 million in Q2 2025.